T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial

Lisa Blixt; David Wullimann; Soo Aleman; Jeanette Lundin; Puran Chen; Yu Gao; Angelica Cuapio; Mira Akber; Joshua Lange; Olga Rivera-Ballesteros; Marcus Buggert; Hans-Gustaf Ljunggren; Lotta Hansson; Anders Österborg

doi:10.3324/haematol.2021.280300

T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial

Haematologica. 2022 Apr 1;107(4):1000-1003. doi: 10.3324/haematol.2021.280300.

Affiliations

¹ Dept of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden; Dept of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
² Center for Infectious Medicine, Dept of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
³ Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine Huddinge, Infectious Diseases, Karolinska Institutet, Stockholm, Sweden.
⁴ Dept of Hematology, Karolinska University Hospital Solna, Stockholm, Sweden; Dept of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. lotta.hansson@regionstockholm.se.

No abstract available

Publication types

Clinical Trial

MeSH terms

Antibodies, Viral
BNT162 Vaccine
COVID-19* / prevention & control
Humans
Immunity
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
Prospective Studies
RNA, Messenger / genetics
SARS-CoV-2
T-Lymphocytes
Vaccination

Substances

Antibodies, Viral
RNA, Messenger
BNT162 Vaccine

Grants and funding

Funding: this study was supported by grants from the SciLifeLab National COVID-19 Research Program, financed by the Knut and Alice Wallenberg Foundation, the Swedish Research Council, Region Stockholm, the Swedish Blood Cancer Foundation and Karolinska Institutet.